csirt@kutim:~/threat-intel/cve/CVE-2026-56291

Katalog CVE

CVSS 9.8 · Critical KEV · sudah dieksploitasi EPSS 14,9%

Kerentanan Unrestricted Upload of File with Dangerous Type pada balbooa forms. Skor CVSS 3.1 9.8 (Critical) menurut NVD. Masuk katalog KEV CISA pada 10 Juli 2026, artinya sudah terbukti dieksploitasi.

Deskripsi (NVD)

Joomla Extension - balbooa.com - Unauthenticated file upload in Balbooa Forms extension < 2.4.1 - The Joomla extension Balbooa Forms is vulnerable to an unauthenticated arbitrary file upload that allows uploading executable files and leads to full RCE.

Rincian

Terbit di NVD
9 Juli 2026
Terakhir diubah
24 Juli 2026
Status NVD
Analyzed
CVSS 3.1
9.8 (Critical), sumber NVD
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H · uraikan di kalkulator
Jenis kelemahan (CWE)
CWE-434: Unrestricted Upload of File with Dangerous Type
EPSS (30 hari)
14,9% peluang dieksploitasi; lebih tinggi dari 96,6% CVE lain

Known Exploited Vulnerabilities (CISA)

Nama
Balbooa Forms Unrestricted Upload of File with Dangerous Type Vulnerability
Masuk KEV
10 Juli 2026
Tenggat CISA
13 Juli 2026 (untuk instansi federal AS)
Ransomware
Belum tercatat
Tindakan wajib
Apply mitigations in accordance with vendor instructions, ensuring compliance with CISA’s BOD 26-04 Prioritizing Security Updates Based on Risk (see URL in Notes) guidance and CISA’s “Forensics Triage Requirements” (see URL in Notes). Follow applicable BOD 26-04 guidance for cloud services or discontinue use of the product if mitigations are unavailable. Stakeholders are responsible for evaluating each asset's internet exposure and ensuring adherence to BOD 26-04 patching guidelines.

Produk dan versi terdampak

VendorProdukVersi terdampak
balbooa forms Semua versi sebelum 2.4.1

> Data dari konfigurasi CPE di NVD.

Referensi dan perbaikan

Sumber: NVD · CVE.org · KEV CISA · EPSS. Halaman ini disusun otomatis dari data tersebut; pembaruan terakhir 5 Okt 2026, 20:11 WITA. Kalau sistem di Perangkat Daerah memakai produk ini dan butuh bantuan, laporkan lewat kanal pelaporan.